New drug cocktail shows promise for tough liver cancers
NCT ID NCT05194293
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 31 times
Summary
This early-phase trial tests whether combining regorafenib (a targeted therapy) with durvalumab (an immunotherapy) can shrink tumors in 4 adults with high-risk liver cancer before surgery. The goal is to see if the treatment reduces tumor size enough to improve surgical outcomes. Participants must have stage IB to IIIA liver cancer and be healthy enough for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.